Financial Ratios Arrowhead Pharmaceuticals, Inc.
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.05 USD | -3.65% |
|
+5.03% | +0.99% |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -15.11 | -15.91 | -17.58 | -39.43 | 4.87 | |||||
Return on Total Capital | -20.31 | -23.88 | -21.89 | -43.85 | 5.37 | |||||
Return On Equity % | -32.36 | -42.67 | -59.33 | -254.98 | 8.67 | |||||
Return on Common Equity | -32.36 | -43.62 | -61.29 | -262.48 | -0.5 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |||||
SG&A Margin | 64.12 | 56.48 | 45.2 | 3.19K | 16.7 | |||||
EBITDA Margin % | -101.79 | -69.11 | -79.97 | -16.4K | 14.74 | |||||
EBITA Margin % | -106.54 | -72.69 | -84.45 | -16.88K | 12.06 | |||||
EBIT Margin % | -107.77 | -73.39 | -85.16 | -16.93K | 11.86 | |||||
Income From Continuing Operations Margin % | -101.85 | -72.56 | -86.93 | -17.17K | 3.63 | |||||
Net Income Margin % | -101.85 | -72.38 | -85.27 | -16.88K | -0.2 | |||||
Net Avail. For Common Margin % | -101.85 | -72.38 | -85.27 | -16.88K | -0.2 | |||||
Normalized Net Income Margin | -63.66 | -43.06 | -51.95 | -10.49K | 0.06 | |||||
Levered Free Cash Flow Margin | 45.55 | -21.93 | -105.7 | -12.39K | 11.59 | |||||
Unlevered Free Cash Flow Margin | 45.55 | -21.93 | -100.95 | -11.83K | 18.33 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.22 | 0.35 | 0.33 | 0 | 0.66 | |||||
Fixed Assets Turnover | 2.45 | 2.07 | 0.96 | 0.01 | 1.93 | |||||
Receivables Turnover (Average Receivables) | 24.91 | 41.7 | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.62 | 2.92 | 3.98 | 6.74 | 4.86 | |||||
Quick Ratio | 2.58 | 2.72 | 3.75 | 6.57 | 4.73 | |||||
Operating Cash Flow to Current Liabilities | 1.17 | -0.98 | -1.46 | -4.49 | 0.92 | |||||
Days Sales Outstanding (Average Receivables) | 14.65 | 8.75 | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 6.25 | 19.5 | 133.55 | 445.88 | 147.79 | |||||
Total Debt / Total Capital | 5.88 | 16.32 | 57.18 | 81.68 | 59.64 | |||||
LT Debt/Equity | 5.7 | 18.84 | 129.87 | 442.56 | 136.35 | |||||
Long-Term Debt / Total Capital | 5.36 | 15.76 | 55.61 | 81.07 | 55.03 | |||||
Total Liabilities / Total Assets | 42.43 | 39.54 | 62.49 | 83.24 | 63.66 | |||||
EBIT / Interest Expense | - | - | -11.19 | -18.58 | 1.1 | |||||
EBITDA / Interest Expense | - | - | -9.43 | -17.49 | 1.55 | |||||
(EBITDA - Capex) / Interest Expense | - | - | -19.07 | -21.86 | 1.3 | |||||
Total Debt / EBITDA | -0.2 | -0.54 | -2.22 | -1.51 | 5.36 | |||||
Net Debt / EBITDA | 2.62 | 1.94 | 0.07 | -0.31 | -1.25 | |||||
Total Debt / (EBITDA - Capex) | -0.17 | -0.4 | -1.1 | -1.2 | 6.41 | |||||
Net Debt / (EBITDA - Capex) | 2.22 | 1.44 | 0.03 | -0.25 | -1.49 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 57.16 | 75.89 | -1.03 | -98.52 | 23.26K | |||||
Gross Profit, 1 Yr. Growth % | 57.16 | 75.89 | -1.03 | -98.52 | 23.26K | |||||
EBITDA, 1 Yr. Growth % | 61.4 | 19.41 | 14.53 | 202.58 | -120.99 | |||||
EBITA, 1 Yr. Growth % | 61.1 | 20 | 14.99 | 194.82 | -116.69 | |||||
EBIT, 1 Yr. Growth % | 59.98 | 19.77 | 14.84 | 193.21 | -116.36 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 66.58 | 25.31 | 18.57 | 191.34 | -104.94 | |||||
Net Income, 1 Yr. Growth % | 66.58 | 25 | 16.59 | 192.04 | -99.73 | |||||
Normalized Net Income, 1 Yr. Growth % | 66.58 | 17.56 | 16.32 | 197.93 | -100.12 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 61.9 | 22.8 | 15.15 | 160.27 | -99.76 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.11K | -86.25 | - | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 40.42 | 155.36 | 99.04 | 28.53 | -1.13 | |||||
Total Assets, 1 Yr. Growth % | 35.91 | -2.56 | 10.64 | 48.89 | 21.54 | |||||
Tangible Book Value, 1 Yr. Growth % | -11.48 | -2.18 | -32.46 | -32.25 | 159.6 | |||||
Common Equity, 1 Yr. Growth % | -11.47 | -2.52 | -31.91 | -31.66 | 151.32 | |||||
Cash From Operations, 1 Yr. Growth % | -279.5 | -179.46 | 13.05 | 200.77 | -138.79 | |||||
Capital Expenditures, 1 Yr. Growth % | 97.18 | 123.94 | 234.88 | -19.96 | -83.98 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -180.07 | -184.67 | 319.66 | 75.06 | -121.85 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -180.07 | -184.67 | 300.77 | 74.99 | -136.2 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -9.49 | 66.26 | 31.94 | -87.92 | 85.62 | |||||
Gross Profit, 2 Yr. CAGR % | -9.49 | 66.26 | 31.94 | -87.92 | 85.62 | |||||
EBITDA, 2 Yr. CAGR % | 46.45 | 38.82 | 16.94 | 86.16 | -20.3 | |||||
EBITA, 2 Yr. CAGR % | 53.06 | 39.04 | 17.47 | 84.12 | -29.85 | |||||
EBIT, 2 Yr. CAGR % | 56.06 | 38.43 | 17.28 | 83.5 | -30.74 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 43.95 | 44.48 | 21.89 | 85.86 | -62.07 | |||||
Net Income, 2 Yr. CAGR % | 43.95 | 44.3 | 20.72 | 84.53 | -91.09 | |||||
Normalized Net Income, 2 Yr. CAGR % | 43.76 | 40.77 | 19.19 | 86.16 | -93.91 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 40.39 | 41 | 18.91 | 73.11 | -92.04 | |||||
Accounts Receivable, 2 Yr. CAGR % | 293.78 | 29.1 | - | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 68.64 | 89.36 | 125.45 | 59.94 | 12.73 | |||||
Total Assets, 2 Yr. CAGR % | 42.47 | 15.08 | 3.83 | 28.35 | 34.52 | |||||
Tangible Book Value, 2 Yr. CAGR % | 31.79 | -6.95 | -18.72 | -32.36 | 32.62 | |||||
Common Equity, 2 Yr. CAGR % | 29.28 | -7.1 | -18.53 | -31.78 | 31.06 | |||||
Cash From Operations, 2 Yr. CAGR % | -0.52 | 19.2 | -5.22 | 84.39 | 8.02 | |||||
Capital Expenditures, 2 Yr. CAGR % | 40.13 | 110.14 | 173.85 | 63.72 | -64.19 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -28.64 | -17.66 | 100.98 | 169.42 | -38.16 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -28.64 | -17.66 | 96.41 | 163.15 | -20.41 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 104.62 | 12.95 | 39.86 | -70.5 | 50.52 | |||||
Gross Profit, 3 Yr. CAGR % | 104.62 | 12.95 | 39.86 | -70.5 | 50.52 | |||||
EBITDA, 3 Yr. CAGR % | 40.06 | 36.82 | 30.2 | 60.54 | -10.06 | |||||
EBITA, 3 Yr. CAGR % | 39.53 | 41.14 | 30.51 | 59.64 | -17.29 | |||||
EBIT, 3 Yr. CAGR % | 38.63 | 42.89 | 30.07 | 59.18 | -18.02 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 37.27 | 37.44 | 35.27 | 62.97 | -44.54 | |||||
Net Income, 3 Yr. CAGR % | 37.27 | 37.33 | 34.4 | 62.06 | -79 | |||||
Normalized Net Income, 3 Yr. CAGR % | 37.27 | 34.98 | 33.25 | 61.76 | -83.73 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 27.83 | 34.26 | 31.79 | 54.39 | -80.6 | |||||
Accounts Receivable, 3 Yr. CAGR % | 215.23 | 28.7 | - | - | 69.15 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 67.95 | 93.65 | 92.53 | 86.94 | 36.25 | |||||
Total Assets, 3 Yr. CAGR % | 85.3 | 25.53 | 13.58 | 17.08 | 26.04 | |||||
Tangible Book Value, 3 Yr. CAGR % | 72.46 | 19.32 | -16.37 | -23.5 | 5.91 | |||||
Common Equity, 3 Yr. CAGR % | 62.2 | 17.67 | -16.24 | -23.16 | 5.36 | |||||
Cash From Operations, 3 Yr. CAGR % | 53.63 | -7.68 | 17.12 | 39.28 | 9.67 | |||||
Capital Expenditures, 3 Yr. CAGR % | 155 | 63.84 | 145.45 | 81.74 | -24.55 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 28.75 | -24.45 | 47.89 | 91.17 | 16.61 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 28.75 | -24.45 | 45.64 | 88.2 | 35.84 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 287.47 | 50.59 | 71.68 | -53.8 | 56.63 | |||||
Gross Profit, 5 Yr. CAGR % | 287.47 | 50.59 | 71.68 | -53.8 | 56.63 | |||||
EBITDA, 5 Yr. CAGR % | 11.33 | 39.08 | 30.31 | 54.75 | 6.99 | |||||
EBITA, 5 Yr. CAGR % | 11.94 | 38.02 | 30.25 | 56.97 | 1.81 | |||||
EBIT, 5 Yr. CAGR % | 11.74 | 36.99 | 29.66 | 57.92 | 1.09 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 11.5 | 38.7 | 30.9 | 55.08 | -18.66 | |||||
Net Income, 5 Yr. CAGR % | 11.5 | 38.63 | 30.4 | 54.56 | -54.6 | |||||
Normalized Net Income, 5 Yr. CAGR % | 10.49 | 37.28 | 29.73 | 54.3 | -61.23 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 0.3 | 28.86 | 24.19 | 48.63 | -57.11 | |||||
Accounts Receivable, 5 Yr. CAGR % | 167.41 | 83.49 | - | - | 51.82 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 33.82 | 61.15 | 88.94 | 79.39 | 55.42 | |||||
Total Assets, 5 Yr. CAGR % | 40.83 | 46.08 | 46.98 | 26.65 | 21.53 | |||||
Tangible Book Value, 5 Yr. CAGR % | 40.02 | 44.69 | 27.65 | -4.91 | 0.57 | |||||
Common Equity, 5 Yr. CAGR % | 33.73 | 37.39 | 23.15 | -5.39 | 0.18 | |||||
Cash From Operations, 5 Yr. CAGR % | 21.59 | 41.57 | 26.65 | 21.75 | 13.39 | |||||
Capital Expenditures, 5 Yr. CAGR % | 43.59 | 46.14 | 162.38 | 63.79 | 13.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 13.31 | 18.76 | 53.85 | 28.9 | 4.1 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 13.31 | 18.76 | 52.44 | 27.69 | 14.08 |
- Stock Market
- Equities
- ARWR Stock
- Financials Arrowhead Pharmaceuticals, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















